Mitsubishi Chemical Medience and LabCorp Clinical Trials Announce Master Service Agreement to Offer Clients Greater Access to

   Mitsubishi Chemical Medience and LabCorp Clinical Trials Announce Master
   Service Agreement to Offer Clients Greater Access to Global Central Lab
                                   Services

PR Newswire

TOKYO, June 21, 2013

TOKYO, June 21, 2013 /PRNewswire/ --Mitsubishi Chemical Medience Corporation
(MCM) today announced that the company has signed a Master Service Agreement
with the clinical trials division of Laboratory Corporation of America^®
Holdings (LabCorp^®) (NYSE:LH). The agreement builds on the strengths and
capabilities of both companies, and allows LabCorp Clinical Trials and MCM to
extend their service offerings to clients in Japan and around the world,
respectfully.

"Pharmaceutical sponsors everywhere continue to look to new markets and
technologies for drug development opportunities, and our clients are no
different," said Mr. Shinichi Yoshihara, President and CEO of Mitsubishi
Chemical Medience Corporation. "We are therefore excited to work closely with
LabCorp as a global leader in central lab, biomarker and specialty testing,
and with cutting-edge technologies from both sides we are confident this
partnership will provide new channels of growth and competitive advantage for
both companies."

"MCM is a leading diagnostic laboratory and central lab in Japan with
considerable experience and long-standing relationships in the medical and
pharmaceutical communities," said Dr. Mark Brecher, LabCorp's Chief Medical
Officer. "The two companies complement each other in this respect, and we
look forward to working together to offer a complete global solution for our
customers conducting trials in Japan and around the globe."

Both companies will exhibit at the Drug Information Association (DIA) annual
meeting taking place June 23-27 in Boston, Mass. Clients who are interested
in learning more about this announcement can visit LabCorp Clinical Trials at
booth 1451 or MCM at booth 1548.

About Mitsubishi Chemical Medience Corporation
Mitsubishi Chemical Medience Corporation is a member of the Mitsubishi
Chemical Holdings Corporation Group, which is headquartered in Tokyo, Japan.
Mitsubishi Chemical Medience is the first company in Japan to establish a
business style that combines clinical and diagnostic laboratory testing
services with in vitro diagnostics (IVD) and pharmaceutical development
support. One of Mitsubishi Chemical Medience's primary business areas is their
IVD business, which includes the development, sale, export, and import of in
vitro diagnostic reagents and instruments. Mitsubishi Chemical Medience's
globally accepted PATHFAST system, a rapid point-of-care immunochemistry
analyzer, has been exported to more than 40 countries. Throughout almost five
decades of IVD business, customers in various chemical and diagnostic industry
segments have come to trust and rely on Mitsubishi Chemical Medience's
competence and strength, as represented by the superior quality of their
products and customized solutions. To learn more, visit the company's website
at http://www.medience.co.jp/english/index.html.

SOURCE Mitsubishi Chemical Medience Corporation

Website: http://www.medience.co.jp/english
Contact: Jamie Hipple, 1-609-456-0822 x105, Jhipple@jfkhealth.com
 
Press spacebar to pause and continue. Press esc to stop.